Advances in the proper use of colchicine and adapting dosages in other countries: Comment on the article by Terkeltaub et al

Lioté, Frédéric

doi:10.1002/art.27641

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Trotz des eindeutigen Ergebnisses bleiben einige Fragen offen und werden in einem Kommentar zu dieser Studie angesprochen [2]. In Deutschland sind nur unteilbare Tabletten zu 0,5 mg Colchicin auf dem Markt, eine exakte Umsetzung der angegebenen Dosierungen ist somit nicht möglich.…”

Section: Kommentarunclassified

Seltene Erkrankungen

Manger

2012

Z. Rheumatol.

View full text Add to dashboard Cite

Section: Kommentarunclassified

Seltene Erkrankungen

Manger

2012

Z. Rheumatol.

View full text Add to dashboard Cite

“…Die EULAR(The European League Against Rheumatism)-Empfehlungen legen sich nicht dahingehend fest, für welche Dauer eine Colchicintherapie fortgeführt werden sollte. Nach der Loading Dose wird eine prophylaktische Gabe empfohlen [21].…”

Section: Diagnostischer Goldstandard Ist Der Nachweis Von Uratkristalunclassified

“…In den USA, beispielsweise, wurde die Gichtprävalenz in 2007/2008 mit 3,9% angegeben (Männer 5,9%, Frauen 2%) und die Hyperurikämieprävalenz mit 21,2% (Männer) bzw 21. 6% (Frauen; [1]).…”

unclassified

Ätiologie und Management der Gicht

Maldonado

2012

Z. Rheumatol.

View full text Add to dashboard Cite

Gout is an inflammatory arthritis caused by monosodium urate (MSU) crystal deposits in and around the joint. The formation of urinary calculi can also occur in gout, but are less common than arthritis. Gout usually presents with recurrent episodes of joint inflammation, which over time lead to tophus formation and joint destruction. In the last decade, significant advances have been made regarding not only the epidemiology and genetics of gout and hyperuricemia but also the mechanisms of inflammation and treatment of gout. In addition, knowledge concerning the key role of interleukin 1 (IL-1) has provided new therapeutic perspectives. However, the current management of gout is often suboptimal, with many Patienten either not receiving adequate treatment or being unable to tolerate existing treatments. New therapeutic agents provide interesting new options for Patienten with difficult-to-treat gouty arthritis.The English full-text version of this is available at SpringerLink (under "Supplemental").

show abstract

Overview of Gout Therapy Strategy and Targets, and the Management of Refractory Disease

Lioté¹,

Terkeltaub²

2012

Gout &Amp; Other Crystal Arthropathies

View full text Add to dashboard Cite

Advances in the proper use of colchicine and adapting dosages in other countries: Comment on the article by Terkeltaub et al

Cited by 5 publications

References 6 publications

Seltene Erkrankungen

Seltene Erkrankungen

Ätiologie und Management der Gicht

Overview of Gout Therapy Strategy and Targets, and the Management of Refractory Disease

Contact Info

Product

Resources

About